OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
Identifieur interne : 000175 ( PubMed/Corpus ); précédent : 000174; suivant : 000176OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
Auteurs : Giampiero Carosi ; Raffaele Bruno ; Giuseppe Cariti ; Paola Nasta ; Roberto Gulminetti ; Massimo Galli ; Gioacchino Angarano ; Gabriella Verucchi ; Emanuele Pontali ; Amedeo Capetti ; Enzo Raise ; Veronica Ravasio ; Ivana Maida ; Claudio Iannacone ; Antonietta Caputo ; Massimo PuotiSource :
- Antiviral therapy ; 2014.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Coinfection, Drug Therapy, Combination, Female, Genotype, HIV Infections (drug therapy), HIV Infections (immunology), HIV Infections (virology), Hepacivirus (genetics), Hepatitis C (drug therapy), Hepatitis C (virology), Humans, Interferon-alpha (administration & dosage), Interferon-alpha (adverse effects), Interferon-alpha (therapeutic use), Liver (pathology), Liver (virology), Male, Middle Aged, Polyethylene Glycols (administration & dosage), Polyethylene Glycols (adverse effects), Polyethylene Glycols (therapeutic use), Prospective Studies, Recombinant Proteins (administration & dosage), Recombinant Proteins (adverse effects), Recombinant Proteins (therapeutic use), Recurrence, Ribavirin (administration & dosage), Ribavirin (adverse effects), Ribavirin (therapeutic use), Treatment Outcome, Viral Load, Young Adult.
- MESH :
- chemical , administration & dosage : Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemical , adverse effects : Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- drug therapy : HIV Infections, Hepatitis C.
- genetics : Hepacivirus.
- immunology : HIV Infections.
- pathology : Liver.
- chemical , therapeutic use : Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- virology : HIV Infections, Hepatitis C, Liver.
- Adolescent, Adult, Aged, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Coinfection, Drug Therapy, Combination, Female, Genotype, Humans, Male, Middle Aged, Prospective Studies, Recurrence, Treatment Outcome, Viral Load, Young Adult.
Abstract
The Optimized Pegylated interferons Efficacy and anti-Retroviral Approach (OPERA) study aimed to assess the efficacy and safety profile of treatment with pegylated interferons (PEG-IFNs) in interferon-naive patients with chronic HCV and HIV infection in routine clinical practice.
DOI: 10.3851/IMP2757
PubMed: 24583976
Links to Exploration step
pubmed:24583976Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.</title><author><name sortKey="Carosi, Giampiero" sort="Carosi, Giampiero" uniqKey="Carosi G" first="Giampiero" last="Carosi">Giampiero Carosi</name><affiliation><nlm:affiliation>Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bruno, Raffaele" sort="Bruno, Raffaele" uniqKey="Bruno R" first="Raffaele" last="Bruno">Raffaele Bruno</name></author><author><name sortKey="Cariti, Giuseppe" sort="Cariti, Giuseppe" uniqKey="Cariti G" first="Giuseppe" last="Cariti">Giuseppe Cariti</name></author><author><name sortKey="Nasta, Paola" sort="Nasta, Paola" uniqKey="Nasta P" first="Paola" last="Nasta">Paola Nasta</name></author><author><name sortKey="Gulminetti, Roberto" sort="Gulminetti, Roberto" uniqKey="Gulminetti R" first="Roberto" last="Gulminetti">Roberto Gulminetti</name></author><author><name sortKey="Galli, Massimo" sort="Galli, Massimo" uniqKey="Galli M" first="Massimo" last="Galli">Massimo Galli</name></author><author><name sortKey="Angarano, Gioacchino" sort="Angarano, Gioacchino" uniqKey="Angarano G" first="Gioacchino" last="Angarano">Gioacchino Angarano</name></author><author><name sortKey="Verucchi, Gabriella" sort="Verucchi, Gabriella" uniqKey="Verucchi G" first="Gabriella" last="Verucchi">Gabriella Verucchi</name></author><author><name sortKey="Pontali, Emanuele" sort="Pontali, Emanuele" uniqKey="Pontali E" first="Emanuele" last="Pontali">Emanuele Pontali</name></author><author><name sortKey="Capetti, Amedeo" sort="Capetti, Amedeo" uniqKey="Capetti A" first="Amedeo" last="Capetti">Amedeo Capetti</name></author><author><name sortKey="Raise, Enzo" sort="Raise, Enzo" uniqKey="Raise E" first="Enzo" last="Raise">Enzo Raise</name></author><author><name sortKey="Ravasio, Veronica" sort="Ravasio, Veronica" uniqKey="Ravasio V" first="Veronica" last="Ravasio">Veronica Ravasio</name></author><author><name sortKey="Maida, Ivana" sort="Maida, Ivana" uniqKey="Maida I" first="Ivana" last="Maida">Ivana Maida</name></author><author><name sortKey="Iannacone, Claudio" sort="Iannacone, Claudio" uniqKey="Iannacone C" first="Claudio" last="Iannacone">Claudio Iannacone</name></author><author><name sortKey="Caputo, Antonietta" sort="Caputo, Antonietta" uniqKey="Caputo A" first="Antonietta" last="Caputo">Antonietta Caputo</name></author><author><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="doi">10.3851/IMP2757</idno><idno type="RBID">pubmed:24583976</idno><idno type="pmid">24583976</idno><idno type="wicri:Area/PubMed/Corpus">000175</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.</title><author><name sortKey="Carosi, Giampiero" sort="Carosi, Giampiero" uniqKey="Carosi G" first="Giampiero" last="Carosi">Giampiero Carosi</name><affiliation><nlm:affiliation>Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bruno, Raffaele" sort="Bruno, Raffaele" uniqKey="Bruno R" first="Raffaele" last="Bruno">Raffaele Bruno</name></author><author><name sortKey="Cariti, Giuseppe" sort="Cariti, Giuseppe" uniqKey="Cariti G" first="Giuseppe" last="Cariti">Giuseppe Cariti</name></author><author><name sortKey="Nasta, Paola" sort="Nasta, Paola" uniqKey="Nasta P" first="Paola" last="Nasta">Paola Nasta</name></author><author><name sortKey="Gulminetti, Roberto" sort="Gulminetti, Roberto" uniqKey="Gulminetti R" first="Roberto" last="Gulminetti">Roberto Gulminetti</name></author><author><name sortKey="Galli, Massimo" sort="Galli, Massimo" uniqKey="Galli M" first="Massimo" last="Galli">Massimo Galli</name></author><author><name sortKey="Angarano, Gioacchino" sort="Angarano, Gioacchino" uniqKey="Angarano G" first="Gioacchino" last="Angarano">Gioacchino Angarano</name></author><author><name sortKey="Verucchi, Gabriella" sort="Verucchi, Gabriella" uniqKey="Verucchi G" first="Gabriella" last="Verucchi">Gabriella Verucchi</name></author><author><name sortKey="Pontali, Emanuele" sort="Pontali, Emanuele" uniqKey="Pontali E" first="Emanuele" last="Pontali">Emanuele Pontali</name></author><author><name sortKey="Capetti, Amedeo" sort="Capetti, Amedeo" uniqKey="Capetti A" first="Amedeo" last="Capetti">Amedeo Capetti</name></author><author><name sortKey="Raise, Enzo" sort="Raise, Enzo" uniqKey="Raise E" first="Enzo" last="Raise">Enzo Raise</name></author><author><name sortKey="Ravasio, Veronica" sort="Ravasio, Veronica" uniqKey="Ravasio V" first="Veronica" last="Ravasio">Veronica Ravasio</name></author><author><name sortKey="Maida, Ivana" sort="Maida, Ivana" uniqKey="Maida I" first="Ivana" last="Maida">Ivana Maida</name></author><author><name sortKey="Iannacone, Claudio" sort="Iannacone, Claudio" uniqKey="Iannacone C" first="Claudio" last="Iannacone">Claudio Iannacone</name></author><author><name sortKey="Caputo, Antonietta" sort="Caputo, Antonietta" uniqKey="Caputo A" first="Antonietta" last="Caputo">Antonietta Caputo</name></author><author><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name></author></analytic><series><title level="j">Antiviral therapy</title><idno type="e-ISSN">2040-2058</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antiretroviral Therapy, Highly Active</term><term>CD4 Lymphocyte Count</term><term>Coinfection</term><term>Drug Therapy, Combination</term><term>Female</term><term>Genotype</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (immunology)</term><term>HIV Infections (virology)</term><term>Hepacivirus (genetics)</term><term>Hepatitis C (drug therapy)</term><term>Hepatitis C (virology)</term><term>Humans</term><term>Interferon-alpha (administration & dosage)</term><term>Interferon-alpha (adverse effects)</term><term>Interferon-alpha (therapeutic use)</term><term>Liver (pathology)</term><term>Liver (virology)</term><term>Male</term><term>Middle Aged</term><term>Polyethylene Glycols (administration & dosage)</term><term>Polyethylene Glycols (adverse effects)</term><term>Polyethylene Glycols (therapeutic use)</term><term>Prospective Studies</term><term>Recombinant Proteins (administration & dosage)</term><term>Recombinant Proteins (adverse effects)</term><term>Recombinant Proteins (therapeutic use)</term><term>Recurrence</term><term>Ribavirin (administration & dosage)</term><term>Ribavirin (adverse effects)</term><term>Ribavirin (therapeutic use)</term><term>Treatment Outcome</term><term>Viral Load</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Liver</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term><term>Hepatitis C</term><term>Liver</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antiretroviral Therapy, Highly Active</term><term>CD4 Lymphocyte Count</term><term>Coinfection</term><term>Drug Therapy, Combination</term><term>Female</term><term>Genotype</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Recurrence</term><term>Treatment Outcome</term><term>Viral Load</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Optimized Pegylated interferons Efficacy and anti-Retroviral Approach (OPERA) study aimed to assess the efficacy and safety profile of treatment with pegylated interferons (PEG-IFNs) in interferon-naive patients with chronic HCV and HIV infection in routine clinical practice.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24583976</PMID><DateCreated><Year>2015</Year><Month>01</Month><Day>13</Day></DateCreated><DateCompleted><Year>2015</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2040-2058</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>8</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Antiviral therapy</Title><ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation></Journal><ArticleTitle>OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.</ArticleTitle><Pagination><MedlinePgn>735-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3851/IMP2757</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Optimized Pegylated interferons Efficacy and anti-Retroviral Approach (OPERA) study aimed to assess the efficacy and safety profile of treatment with pegylated interferons (PEG-IFNs) in interferon-naive patients with chronic HCV and HIV infection in routine clinical practice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a multicentre, prospective observational cohort study conducted at 98 Italian referral centres for the treatment of chronic HCV and HIV coinfection. Adult subjects (n=1,523) with a confirmed diagnosis of HCV and stable HIV coinfection were followed between April 2005 and March 2011; of these, 1,284 were interferon-naive and were the focus of this analysis. Patients received PEG-IFN-α2a or -α2b plus ribavirin combination therapy. The choice of treatment and dose was at the investigator's discretion, according to the summary of product characteristics and current guidelines. The primary efficacy end point was sustained virological response (SVR). Secondary end points included rates of rapid viral response, early viral response and response at end of treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">SVR was achieved by 40.0% of patients; the highest SVR rate was observed in patients with HCV genotypes 2 and 3. More genotype 2 and 3 than genotype 1 and 4 patients achieved rapid and early viral responses, and end of treatment responses. Higher SVR rates were also associated with ≥80% anti-HCV treatment compliance and lower baseline HCV levels.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The OPERA study results show that PEG-IFN plus ribavirin is an effective treatment for HCV-HIV coinfection in interferon-naive patients. Independent predictors of SVR include HCV genotype, undetectable baseline HIV RNA and baseline HCV RNA<500,000 IU/ml.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carosi</LastName><ForeName>Giampiero</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruno</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cariti</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Nasta</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gulminetti</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Galli</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Angarano</LastName><ForeName>Gioacchino</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Verucchi</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Pontali</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Capetti</LastName><ForeName>Amedeo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Raise</LastName><ForeName>Enzo</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ravasio</LastName><ForeName>Veronica</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Maida</LastName><ForeName>Ivana</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Iannacone</LastName><ForeName>Claudio</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Caputo</LastName><ForeName>Antonietta</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Puoti</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antivir Ther</MedlineTA><NlmUniqueID>9815705</NlmUniqueID><ISSNLinking>1359-6535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance></Chemical><Chemical><RegistryNumber>30IQX730WE</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D023241">Antiretroviral Therapy, Highly Active</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018791">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D060085">Coinfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015658">HIV Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016174">Hepacivirus</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006526">Hepatitis C</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011092">Polyethylene Glycols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012254">Ribavirin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019562">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>1</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2014</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.3851/IMP2757</ArticleId><ArticleId IdType="pubmed">24583976</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000175 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000175 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24583976
|texte= OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24583976" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a OperaV1
| This area was generated with Dilib version V0.6.21. |  |